{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Koivula RW"],"funding":["Novo Nordisk Foundation","Novo Nordisk","European Research Council","Medical Research Council","National Institute for Health Research (NIHR)","NNF Center for Basic Metabolic Research","Novo Nordisk Foundation Center for Protein Research","Wellcome Trust","Innovative Medicines Initiative Joint Undertaking","Novo Nordisk Fonden"],"pagination":["1601-1615"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6677872"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["62(9)"],"pubmed_abstract":["<h4>Aims/hypothesis</h4>Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) epidemiological cohorts at baseline and follow-up examinations (18, 36 and 48 months of follow-up).<h4>Methods</h4>From a sampling frame of 24,682 adults of European ancestry enrolled in population-based cohorts across Europe, participants at varying risk of glycaemic deterioration were identified using a risk prediction algorithm (based on age, BMI, waist circumference, use of antihypertensive medication, smoking status and parental history of type 2 diabetes) and enrolled into a prospective cohort study (n = 2127) (cohort 1, prediabetes risk). We also recruited people from clinical registries with type 2 diabetes diagnosed 6-24 mo"],"journal":["Diabetologia"],"pubmed_title":["Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium."],"pmcid":["PMC6677872"],"funding_grant_id":["Hansen Group","ERC-2015-CoG_NASCENT_681742 (P.W.F.)","NNF18OC0031650","MC_UU_12015/3","Pedersen Group","NNF17OC0027594","PI Søren Brunak","IMI-DIRECT n°115317","102820/Z/13/Z","681742","NNF17OC0027594 (S.Bru.)","NF-SI-0616-10080","STAR Award co-financed PhD fellowship (R.K.)","Investigator award 102820/Z/13/Z (E.R.P)"],"pubmed_authors":["McCarthy MI","Frost G","Koopman ADM","Perry MH","Vinuela A","Bell JD","Hansen TH","Brunak S","Forgie IM","Groves CJ","Mahajan A","IMI DIRECT Consortium","Rutters F","Kurbasic A","Koivula RW","Pavo I","Walker M","Kaye J","Teare HJA","De Masi F","Heggie A","Adamski J","Brorsson CA","Kokkola T","Ridderstrale M","Laakso M","Mari A","Franks PW","Allin KH","Dawed AY","White T","Tura A","Hattersley A","McDonald TJ","Ruetten H","Dermitzakis ET","Jablonka B","Schwenk JM","Gupta R","Siloaho M","Pedersen O","Brage S","Beulens JW","Thomas EL","Giordano GN","Hansen T","Hudson M","Vestergaard H","Pearson E","Froguel P","Rauh SP"],"additional_accession":[]},"is_claimable":false,"name":"Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium.","description":"<h4>Aims/hypothesis</h4>Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) epidemiological cohorts at baseline and follow-up examinations (18, 36 and 48 months of follow-up).<h4>Methods</h4>From a sampling frame of 24,682 adults of European ancestry enrolled in population-based cohorts across Europe, participants at varying risk of glycaemic deterioration were identified using a risk prediction algorithm (based on age, BMI, waist circumference, use of antihypertensive medication, smoking status and parental history of type 2 diabetes) and enrolled into a prospective cohort study (n = 2127) (cohort 1, prediabetes risk). We also recruited people from clinical registries with type 2 diabetes diagnosed 6-24 mo","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Sep","modification":"2025-04-04T11:05:42.973Z","creation":"2019-08-21T07:01:34Z"},"accession":"S-EPMC6677872","cross_references":{"pubmed":["31203377"],"doi":["10.1007/s00125-019-4906-1"]}}